Marble Wealth LLC Invests $2.43 Million in Eli Lilly and Company $LLY

Marble Wealth LLC purchased a new position in Eli Lilly and Company (NYSE:LLY) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 2,265 shares of the company’s stock, valued at approximately $2,434,000.

Several other hedge funds have also recently modified their holdings of the business. Brighton Jones LLC lifted its position in Eli Lilly and Company by 22.0% during the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock valued at $7,409,000 after acquiring an additional 1,730 shares during the last quarter. Revolve Wealth Partners LLC lifted its position in Eli Lilly and Company by 2.8% during the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock valued at $1,136,000 after acquiring an additional 40 shares during the last quarter. Schnieders Capital Management LLC. lifted its position in Eli Lilly and Company by 16.7% during the second quarter. Schnieders Capital Management LLC. now owns 7,993 shares of the company’s stock valued at $6,231,000 after acquiring an additional 1,141 shares during the last quarter. Flow Traders U.S. LLC purchased a new stake in Eli Lilly and Company during the second quarter valued at approximately $356,000. Finally, Nebula Research & Development LLC purchased a new stake in Eli Lilly and Company during the second quarter valued at approximately $749,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on LLY shares. BMO Capital Markets reissued an “outperform” rating and set a $1,300.00 target price on shares of Eli Lilly and Company in a research report on Thursday, February 5th. CICC Research upped their price target on shares of Eli Lilly and Company from $1,060.00 to $1,107.00 and gave the company a “neutral” rating in a research note on Wednesday, February 11th. The Goldman Sachs Group restated a “buy” rating and set a $1,283.00 price target on shares of Eli Lilly and Company in a research note on Friday, May 22nd. Deutsche Bank Aktiengesellschaft restated a “buy” rating and set a $1,285.00 price target on shares of Eli Lilly and Company in a research note on Friday, March 6th. Finally, Sanford C. Bernstein restated an “outperform” rating on shares of Eli Lilly and Company in a research note on Tuesday, March 10th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $1,227.00.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: CVS Caremark has expanded coverage of Eli Lilly’s full obesity portfolio, including the newly approved oral therapy Foundayo and Zepbound, meaning all three of the largest U.S. pharmacy benefit managers now cover Lilly’s obesity medicines. That broadens access for millions of patients and strengthens the commercial case for Lilly’s GLP-1 franchise. Article Title
• Positive Sentiment: Lilly also announced new and expanding drug-development partnerships in Asia, including licensing deals with Hanmi and Haisco, which add to its pipeline and could create future revenue opportunities. Article Title
• Positive Sentiment: Positive Phase 3 results for Retevmo in lung cancer and upcoming hematology presentations at the EHA meeting suggest Lilly continues to build value in its non-obesity portfolio as well. Article Title
• Neutral Sentiment: Several commentary pieces highlighted Lilly as a top stock and pointed to strong CEO remarks and “Nvidia-like” growth, which may support sentiment but do not change fundamentals on their own. Article Title
• Neutral Sentiment: Some articles note competitive pressure in the GLP-1 market, including Viking Therapeutics’ upcoming catalyst and Novo Nordisk’s continued lead in the oral weight-loss pill race, but these are more watch items than immediate threats. Article Title
• Negative Sentiment: One ETF-focused article argued investors should avoid a pharmaceutical fund despite Lilly’s strength because the rest of the holdings are less attractive; this is not a direct negative for Lilly, but it reflects that some market commentary is more cautious on the broader pharma trade. Article Title

Eli Lilly and Company Stock Down 1.6%

NYSE:LLY opened at $1,064.52 on Wednesday. The firm has a market capitalization of $1.00 trillion, a P/E ratio of 37.82, a PEG ratio of 1.18 and a beta of 0.53. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,149.10. The company’s fifty day moving average price is $959.18 and its 200-day moving average price is $1,010.74. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, topping analysts’ consensus estimates of $6.97 by $1.58. The firm had revenue of $19.80 billion for the quarter, compared to analyst estimates of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The business’s quarterly revenue was up 55.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, equities research analysts anticipate that Eli Lilly and Company will post 35.8 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th will be paid a $1.73 dividend. The ex-dividend date is Friday, May 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.7%. Eli Lilly and Company’s dividend payout ratio is presently 24.58%.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.